Refinement of a novel biomarker assay for myopia screening

Early detection and intervention is critical in the management of the visual disorder myopia (short-sightedness). However, there are currently no reliable tools available to detect or predict myopia onset. Fortunately, through work in animal models, we have found that several robust ocular biomarkers associated with myopia development can actually be detected in tears. This is an important development, as a panel of tear biomarkers would provide a valuable screening tool that would dramatically enhance our ability to control and clinically manage myopia. We are therefore applying for DTF funding to validate and protect this IP to advance towards commercialisation.